Latizolil

Latanoprost, the active ingredient in Latizolil, is a prostaglandin analog presented as eye drops for ocular (topical ophthalmic) use. It treats primary open-angle glaucoma and ocular hypertension in adults by lowering intraocular pressure.

GNH USA supplies Latizolil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latizolil is a prostaglandin analog used to manage conditions that involve elevated intraocular pressure.

Primary open-angle glaucoma: reduces intraocular pressure, helping to slow disease progression. Ocular hypertension: lowers intraocular pressure to prevent conversion to glaucoma.

Common Side Effects: - Eye irritation or burning sensation - Redness of the conjunctiva - Itching or mild discomfort - Blurred vision after instillation - Increased brown pigmentation of the iris - Growth of eyelashes (hypertrichosis)

Serious or Rare Side Effects: - Uveitis or intraocular inflammation - Severe allergic reaction (e.g., angioedema) - Persistent ocular pain - Sudden loss of vision - Corneal edema - Endophthalmitis (infection inside the eye)

Before using Latizolil, consider the following precautions.

Monitor intraocular pressure: regular ophthalmic assessments are required. Assess for ocular infections: avoid use if active eye infection is present. Avoid contact lenses: remove lenses before instillation and wait before reinserting. Pregnancy and lactation: safety unknown; use only if potential benefit justifies the risk. Concomitant ocular medications: may alter efficacy or increase irritation. Store at room temperature: keep in original container, protect from light and moisture.

Latizolil may interact with other ophthalmic agents.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analogs: may increase pigmentary changes and irritation. - Use with ocular anesthetics: can diminish the IOP‑lowering effect.

Moderate Interactions (Monitor Closely): - Nonsteroidal anti‑inflammatory eye drops: may affect intraocular pressure control. - Systemic beta‑blockers: additive IOP‑lowering effect may require monitoring. - Topical corticosteroids: may reduce the efficacy of Latanoprost.